TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9285071
Drug: B3/L3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: B3/L3 supplementation (3 mg beta-carotene, 3 mg lycopene, 5 mg vitamin E, 30 mg vitamin C)
Study: 20170481
Drug: Removable dental
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable dental prostheses for molar replacement (treatment A)
Study: 20170481
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments A and B
Study: 18498925
Drug: Erlotinib added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib added to gemcitabine treatment regimen for 40% (n=10) of gemcitabine-treated patients for 15.7 weeks of therapy
Study: 18498925
Drug: Erlotinib added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib added to gemcitabine treatment regimen
Study: 10813547
Drug: Drug/polymer system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug/polymer system
Study: 6383692
Drug: High-dose naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose naloxone infusion during severe exercise
Study: 6383692
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion during severe exercise
Study: 6682026
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion
Study: 31674256
Drug: Corticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment (CT) group with low-dose dexamethasone (5mg/d) for 5 days
Study: 27451942
Drug: ESAT6‐CFP10 (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESAT6‐CFP10 (0.1, 0.5, 1 or 2 μg)
Study: 17687925
Drug: VEGF inhibitors
Normalized name: Vegf receptor 2 kinase inhibitor i
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF inhibitors (pegaptanib, ranibizumab, bevacizumab)
Study: 15158629
Drug: Elemental zinc
Normalized name: Zinc, 220 mg (as elemental zinc 50 mg) oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elemental zinc (20 mg per day)
Study: 9040630
Drug: Glucose-insulin-potassium solution
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium solution (30% dextrose in water; K+, 80 mEq/L; regular insulin, 50 units) given intravenously at 1 ml/kg per hour for 12 hours after aortic unclamping
Study: 9040630
Drug: Glucose-insulin-potassium solution
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium solution
Study: 23230756
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of autologous platelet-rich gel (APG)
Study: 12745511
Drug: 300mg bupropion
Normalized name: bupropion hydrochloride 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg bupropion SR + 21 mg/24-hr nicotine patch
Study: 12504657
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 10 mg/m2 on day 1 and continuous infusion of 5-fluorouracil (5-FU) 200 mg/m2 from days 1-26 in the first sequence (36 Gy over 4 weeks) and 5-FU 200 mg/m2 from days 1-17 in the second sequence (23.4 Gy over 17 days)
Study: 18341673
Drug: Brivaracetam 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 400 mg/day
Study: 20392617
Drug: 1 portion
Normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 portion of fruit and vegetable (FV) daily for 8 weeks
Study: 20392617
Drug: 3 portions
Normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 portions of fruit and vegetable (FV) daily for 8 weeks
Study: 20392617
Drug: 6 portions
Normalized name: XMAB5871 (HUMANIZED ANTI-CD19 ANTIBODY WITH AN FC PORTION ENGINEERED FOR INCREASED AFFINITY (200- TO 400-FOLD OVER NATIVE IGG) TO FCGRIIB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 portions of fruit and vegetable (FV) daily for 8 weeks
Study: 17130849
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg lidocaine per nostril
Study: 17130849
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lidocaine per nostril
Study: 17130849
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg lidocaine per nostril
Study: 15101566
Drug: Sulpiride augmentation
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride augmentation (600 mg/day) with olanzapine
Study: 31818823
Drug: Gepotidacin 750
Normalized name: gepotidacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin 750 mg every 12 hours (q12h)
Study: 17577103
Drug: Duloxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 120 mg BID
Study: 17577103
Drug: Duloxetine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 200 mg BID
Study: 17577103
Drug: Duloxetine 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 160 mg BID
Study: 9522134
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine (50 mg) intra‐articular (IA)
Study: 2478604
Drug: 10 or
Normalized name: K-10 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 or 100 times the concentration of allergen required for 4+ early intradermal reaction
Study: 799983
Drug: Betamethasone-17, 21-dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone-17, 21-dipropionate and salicylic acid treatment
Study: 31502392
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream (TCC) (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%)
Study: 31605113
Drug: RSV/ΔNS2/Δ1313/I1314L vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV/ΔNS2/Δ1313/I1314L vaccine at 106 PFU
Study: 31605113
Drug: RSV/ΔNS2/Δ1313/I1314L vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV/ΔNS2/Δ1313/I1314L vaccine at 105 PFU
Study: 27756788
Drug: Urelumab 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urelumab 0.1 mg/kg every 3 weeks
Study: 27756788
Drug: Urelumab doses
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Urelumab doses between 1 and 15 mg/kg every 3 weeks
Study: 27756788
Drug: Urelumab doses
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Urelumab doses ≥1 mg/kg
Study: 24283127
Drug: Gel beads
Normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel beads containing Eimeria oocysts
Study: 24283127
Drug: Spray vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray vaccination with Eimeria oocysts
Study: 24283127
Drug: Gel beads
Normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel beads or spray vaccination
Study: 12742981
Drug: VEGF plasmid
Normalized name: plasmin
DrugBank: Fibrinolysin (DB05254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF plasmid liposome (VEGF‐P/L; 2000 microg of DNA with 2000 microL of DOTMA:DOPE [1:1 wt/wt])
Study: 8769695
Drug: Hydroxyurea monotherapy
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea monotherapy
Study: 10669337
Drug: Didanosine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine monotherapy
Study: 28561068
Drug: GHB (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB (35 mg/kg p.o.)
Study: 24446590
Drug: Conventional gingival
Normalized name: Bos taurus gingiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional gingival displacement (gingival cord + 25% AlCl3 astringent gel)
Study: 22562021
Drug: Adalimumab high
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab high dose (40 mg or 20 mg for body weight >/=40 kg or <40 kg; n = 93)
Study: 22562021
Drug: Adalimumab low
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab low dose (20 mg or 10 mg for body weight >/=40 kg or <40 kg; n = 95)
Study: 15570084
Drug: Tipifarnib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib (all doses)
Study: 11213010
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg prednisolone daily in two divided oral doses
Study: 16671837
Drug: Improvisational music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improvisational music therapy
Study: 4054138
Drug: PY-108-068 75
Normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PY-108-068 75 mg
Study: 4054138
Drug: PY-108-068 150
Normalized name: KETOCONAZ 2% GEL/ZINC PY 1% SHAMPOO KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: PY-108-068 150 mg
Study: 20731496
Drug: Multisystemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic Therapy for Child Abuse and Neglect (MST‐CAN)
Study: 29619643
Drug: Enhanced outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced outpatient treatment
Study: 1590572
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg and flunitrazepam 0.5 mg p.o. given at 10:00 p.m. on the evening prior to surgery
Study: 1590572
Drug: Famotidine treatment
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Famotidine treatment group
Study: 2070703
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg nocte)
Study: 20438539
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of sevelamer and calcium carbonate
Study: 20438539
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of sevelamer and calcium carbonate
Study: 10470387
Drug: Group P100:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P100: propofol 1% 20 ml/lignocaine 1% 4 ml
Study: 2013178
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of acute sublingual nitrendipine
Study: 2013178
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of nitrendipine once daily for 3 weeks
Study: 6496911
Drug: 5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lignocaine and prilocaine cream applied for 20 minutes or longer
Study: 6496911
Drug: 5% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lignocaine and prilocaine cream
Study: 28900859
Drug: Music used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music used for relaxation and treatment of depression, 12 structured group sessions of 22 min, two times a day for 4 weeks
Study: 21337773
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program about Ca, PO4 and PTH metabolism
Study: 17204525
Drug: Mild stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild stimulation regimen using GnRH antagonist co‐treatment (67 patients)
Study: 17204525
Drug: Conventional high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional high‐dose exogenous gonadotrophin regimen and GnRH agonist co‐treatment (44 patients)
Study: 15700748
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml olive oil with high phenolic content
Study: 15700748
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml olive oil with moderate phenolic content
Study: 15700748
Drug: 25 ml
Normalized name: ethanol 6.025 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 ml olive oil with low phenolic content
Study: 9186538
Drug: G-CSF and
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF and 200 IU/kg of EPO (group L)
Study: 9186538
Drug: G-CSF and
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF and 400 IU/kg of EPO (group H)
Study: 9186538
Drug: G-CSF alone
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF alone (group C)
Study: 2418302
Drug: Nicardipine (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (20-30 mg three times daily)
Study: 2418302
Drug: Nicardipine (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (with pindolol as second-step treatment)
Study: 2418302
Drug: Placebo (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (with pindolol as second-step treatment)
Study: 26981608
Drug: Comprehensive oral
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive oral health care
Study: 30746532
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health examination (Control)
Study: 25299536
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (designed physical therapy program)
Study: 18812844
Drug: Ropivacaine hydrochloride,
Normalized name: Ropivacaine Hydrochloride, 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine hydrochloride, 0.2 mg/kg, by submucous infiltration of the proposed incisional site
Study: 21764706
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no medication before surgery)
Study: 12709722
Drug: Itraconazole, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole, 200 mg once daily for 5 days with 80 mg rosuvastatin coadministered on day 4 (trial B)
Study: 11766002
Drug: Rubella IgG
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubella IgG antibody testing using ELISA technique
Study: 30587926
Drug: Vardenafil hydrochloride
Normalized name: Vardenafil Hydrochloride
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vardenafil hydrochloride (20 mg tablets)
Study: 27783767
Drug: Oral sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sedation with midazolam
Study: 27783767
Drug: Oral sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sedation with midazolam/ketamine
Study: 11726454
Drug: No sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sedative
Study: 20377476
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg and simvastatin 20 mg/day
Study: 11324984
Drug: INS365 ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS365 ophthalmic solution (0.5%, 1.0%, 2.0%, 5.0%)
Study: 11324984
Drug: INS365 ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS365 ophthalmic solution (5.0%)
Study: 11324984
Drug: INS365 ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: INS365 ophthalmic solution
Study: 8433151
Drug: AGM-1470 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AGM-1470 treatment
Study: 3630929
Drug: Isosorbide-5-mononitrate (IS-5MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5MN) 20 mg
Study: 3630929
Drug: Isosorbide-5-mononitrate (IS-5MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5MN) 40 mg
Study: 12368971
Drug: Daily movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily movement (passive range of motion with gentle compression of both the upper and lower extremities, 5 days per week for 4 weeks)
Study: 6759814
Drug: Anapsos 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anapsos 120 mg
Study: 31599965
Drug: Hard water
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard water (> 257 mg L−1 CaCO3)
Study: 31599965
Drug: Soft water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft water (≤ 257 mg L−1 CaCO3)
Study: 25929612
Drug: Micafungin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin (1 mg/kg for candidiasis, 1 to 3 mg/kg for aspergillosis, up to 6 mg/kg once daily if required)
Study: 19364294
Drug: EFA supplementation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EFA supplementation (480 mg of linoleic acid and 120 mg of alpha-linolenic acid)
Study: 10839585
Drug: Abacavir (ABC)
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abacavir (ABC) + Stable Background Therapy (SBG)
Study: 10839585
Drug: Stable Background
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable Background Therapy (SBG) alone
Study: 21936956
Drug: Weekly low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly low dose zoledronic acid
Study: 3087915
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (30 or 50 micrograms ethinyl oestradiol and 150 micrograms levonorgestrel)
Study: 20655766
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid injection (accuracy identified by fluoroscopy)
Study: 10680784
Drug: Lidocaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (5 mg/kg IV over 30 minutes)
Study: 9292253
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment options that block calcium channels or inhibit the sodium-mediated calcium transporter to prevent axonal damage.
Study: 3535364
Drug: Intracervical PGE2‐gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical PGE2‐gel twice with a 12‐hour interval
Study: 3535364
Drug: Intracervical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical placebo gel twice with 12‐hour interval
Study: 20375907
Drug: Experimental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatments (BP-lowering agents)
Study: 17985242
Drug: Intravenous pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pantoprazole 80 mg loading dose over 5 min, followed by 8 mg/h intravenous infusion for 72 h, then 40 mg orally once a day for 4 days.
Study: 17985242
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 40 mg pantoprazole intravenously once a day for 72 h, then orally once a day for 4 days.
Study: 16021478
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus antiemetic medication
Study: 16021478
Drug: Anti-emetic medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-emetic medication alone
Study: 10894441
Drug: Amlodipine (monotherapy)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (monotherapy)
Study: 6293715
Drug: Cefotaxime (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (20 mg/kg every six hours)
Study: 6293715
Drug: Gentamicin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1 mg/kg every eight hours) plus Clindamycin (5 mg/kg every six hours)
Study: 30928863
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg quetiapine daily for 8 weeks
Study: 25925036
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block (ISPB) with 20 mL 0.25% bupivacaine
Study: 25925036
Drug: Intra-articular (IA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular (IA) administration with 20 mL 0.25% bupivacaine
Study: 23106905
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAT; aspirin and prasugrel)
Study: 23106905
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (TAT; aspirin, clopidogrel, cilostazol)
Study: 21798863
Drug: 2 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 25 g/day whey protein (PRO)
Study: 19326422
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (400 microg) combined with intravenous patient-controlled analgesia (IV-PCA)
Study: 26689781
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (IV-PCA) alone
Study: 28844213
Drug: R. ribes
Approvals — FDA: no, EMA: no, PMDA: no
Description: R. ribes syrup
Study: 12521274
Drug: Oxygen mask
Normalized name: oxygen masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen mask treatment
Study: 8339132
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of slow release diclofenac
Study: 3549420
Drug: Trazodone (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (100-150 mg/day)
Study: 12111446
Drug: Cerebrolysin (Cere),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (Cere), 30 mL injected intravenously, five days per week for four weeks
Study: 11874388
Drug: mizolastine 10
Normalized name: mizolastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mizolastine 10 mg
Study: 2012082
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg aerosol pentamidine biweekly
Study: 2012082
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg aerosol pentamidine biweekly
Study: 2012082
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg aerosol pentamidine biweekly
Study: 7084029
Drug: Trimethoprim/sulfamethoxazole (TMP/SMX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim/sulfamethoxazole (TMP/SMX) 6.8/34 mg/kg/d divided into twice daily doses for six months